首頁 > 市場調查報告書 > 醫療設備

生技設備

市場調查報告書

商品編碼

1341911

藥物開發中下一代測序 (NGS) 的全球市場

Global Next-Generation Sequencing on Drug Development Market

出版日期: 2023年08月29日 | 出版商:

BCC Research | 英文 177 Pages | 訂單完成後即時交付

價格

簡介目錄圖表

全球藥物開發下一代測序（NGS）市場預計將從2023年的13億美元成長到2028年的29億美元，年複合成長率為17.7%。

按地區分類，北美市場預計將從2023年的5.398億美元成長到2028年的12億美元，複合年複合成長率為18.0%。此外，亞太市場預計將從2023年的3.11億美元成長到2028年的7.436億美元，年複合成長率為19.0%。

本報告調查了全球下一代測序（NGS）藥物開發市場，提供了市場和技術概述、市場影響因素和市場機會分析、市場規模趨勢和預測，以及按不同細分市場和地區進行的細分。詳細分析、ESG發展、技術/專利動向、競爭形勢、主要企業概況等。

科技背景
DNA 的結構和重要性
DNA測序技術
全基因組測序
靶向重測序
晶片測序
RNA測序
甲基化測序
DNA測序的歷史
桑格測序
下一代測序 (NGS) 概述
NGS的優點
Roche 454 Pyrosequencing
Illumina NGS
Thermo Fisher Scientific (Life Technologies) NGS
測序設備
台式測序儀
資訊技術
NGS在藥物開發中的應用
NGS服務提供商

第4章市場動態

市場促進因素
利用 NGS 技術擴大研發活動
醫療費用增加
測序平台的技術進步
向精準醫療過渡
對 NGS 為癌症患者設計個人化醫療的需求不斷成長
高精度/低成本
市場抑制因素
與 NGS 技術相關的限制
臨床測序技術的其他課題
市場機會
NGS 研發的不斷成長為製造商創造了有利的機會

第5章藥物開發中的 NGS 市場（按產品類型）

設備
消耗品
服務

第6章藥物開發中的 NGS 市場：按最終用戶分類

製藥和生物技術公司
學術研究中心
其他

第7章藥物開發中的 NGS 市場：按地區

市場概覽/討論
北美
亞太地區
歐洲
其他地區

第8章藥物開發的永續性 NGS：ESG 視角

ESG：概述
藥物開發的永續性 NGS：ESG 視角
ESG 關鍵課題
消費者對 ESG 的態度
行業ESG績效分析
案例分析
環境
社會
治理
BCC的結語

第9章新技術和發展

概述
市場上的新興技術
人工智慧在NGS中的應用
單分子即時測序
奈米孔技術
基於顯微鏡的測序

第10章專利分析

第11章併購與資金籌措預測

第12章競爭形勢

世界公司排名
世界公司排名：設備
世界公司排名：消耗品
世界公司排名：服務

第13章公司簡介

10X GENOMICS
AGILENT TECHNOLOGIES INC.
BGI (BEIJING GENOMICS INSTITUTE)
BIO-RAD LABORATORIES INC.
CD GENOMICS
ILLUMINA INC.
INTEGRATED DNA TECHNOLOGIES INC.
MICRONOMA
NEW ENGLAND BIOLABS
OXFORD NANOPORE TECHNOLOGIES
PACIFIC BIOSCIENCES OF CALIFORNIA INC.
PERKINELMER INC.
PROMEGA CORP.
PSOMAGEN INC.
醫學精準（原 APOCELL）
QIAGEN
ROCHE HOLDING AG
THERMO FISHER SCIENTIFIC INC.
TAKARA BIO INC.
TECAN GROUP LTD.

第14章附錄：首字母縮寫詞

簡介目錄圖表

Product Code: BIO246A

Highlights:

The global next-generation sequencing (NGS) market in drug development should reach $2.9 billion by 2028 from $1.3 billion in 2023 at a compound annual growth rate (CAGR) of 17.7% for the forecast period of 2023 to 2028.

North American NGS market in drug development is expected to grow from $539.8 million in 2023 to $1.2 billion in 2028 at a CAGR of 18.0% for the forecast period of 2023 to 2028.

Asia-Pacific NGS market in drug development is expected to grow from $311 million in 2023 to $743.6 million in 2028 at a CAGR of 19.0% for the forecast period of 2023 to 2028.

Report Scope:

The scope of this report includes NGS technologies, applications, industries, initiatives, patents and companies. The markets for NGS in drug development are given for 2020, 2021, 2022, 2023 and 2028.

This report reviews the NGS technologies and explains why NGS is important in drug development. It then discusses some of the significant research initiatives that impact NGS. The main market-driving forces are also discussed.

This report examines the markets by product type, end user and region. This report provides market data and forecasts for NGS by product type, including instruments, consumables and services for drug development.

Specific geographic markets are discussed, including North America, Europe, Asia-Pacific and the Rest of the World.

BCC Research summarizes the main industry acquisitions and strategic alliances from Jan. 2020, through Dec. 2022, including key alliance trends.

Report Includes:

52 data tables and 39 additional tables
An overview of the global markets for next-generation sequencing on drug development
Estimation of market size and analyses of global market trends, with data from 2020-2022, estimates for 2023, and projections of compound annual growth rates (CAGRs) through 2028
Highlights of the market potential and characterization of next-generation sequencing on drug development market by product, service, end-user type, and region
Examination of the key drivers and constraints that will shape the market for next-generation sequencing on drug development and discussion on the upcoming market opportunities and areas of focus to forecast the market into various segments and subsegments
Coverage of recent advances, emerging technologies, and developments of the industry
Evaluation of key industry acquisitions and strategic alliances and market share analysis of the leading suppliers of the industry
Profiles of the key companies of the industry, including 10x Genomics, Bio-Rad Laboratories Inc., Oxford Nanopore Technologies, Qiagen and Takara Bio Inc.

Chapter 1 Introduction

Study Goals and Objectives
Reasons for Doing This Study
Scope of Report
Research Methodology
Information Sources
Geographic Breakdown

Chapter 2 Summary and Highlights

Market Outlook
Market Summary

Chapter 3 Market Overview

Introduction
Technology Background
Structure and Importance of DNA
DNA Sequencing Technologies
Whole Genome Sequencing
Targeted Resequencing
ChIP Sequencing
RNA Sequencing
Methylation Sequencing
History of DNA Sequencing
Sanger Sequencing
Introduction to Next Generation Sequencing (NGS)
Advantages of NGS
Roche 454 Pyrosequencing
Illumina NGS
Thermo Fisher Scientific (Life Technologies) NGS
Sequencing Instruments
Benchtop Sequencers
Informatics Technologies
NGS in Drug Development
NGS Service Providers

Chapter 4 Market Dynamics

Market Drivers
Increasing R&D Activities using NGS technologies
Increase in Healthcare Expenditure
Technological Advancements in Sequencing Platforms
Shift Towards Precision Medicine
Growing demand of NGS for Designing Individualized Medicine to Cancer Patients
High Accuracy and Low Cost
Market Restraints
Limitations Associated with NGS Technology
Other Clinical Sequencing Technology Challenges
Market Opportunities
Rising R&D in NGS creates lucrative Opportunities for Manufacturers

Chapter 5 NGS in Drug Development by Product Type

Introduction
Instruments
Consumables
Services

Chapter 6 NGS Market in Drug Development by End User

Pharmaceutical and Biotechnology Companies
Academic and Research Centers
Other End Users

Chapter 7 NGS Market in Drug Development by Region

Market Overview and Discussion
North America
Asia-Pacific
Europe
Rest of the World

Chapter 8 Sustainability of NGS in Drug Development: An ESG Perspective

Introduction to ESG
Sustainability of NGS in Drug Development: An ESG Perspective
Key ESG Issues
Consumer Attitudes Towards ESG
Industry ESG Performance Analysis
Case Study
Environment
Social
Governance
Concluding Remarks from BCC

Chapter 9 Emerging Technologies and Developments

Overview
Emerging Technologies in the Market
Application of Artificial Intelligence (AI) in NGS
Single-Molecule Real-Time Sequencing
Nanopore Technology
Microscopy-Based Sequencing

Chapter 10 Patent Analysis

Introduction
Patents on NGS by Region

Chapter 11 M&A and Funding Outlook

M&A Analysis

Chapter 12 Competitive Landscape

Global Company Ranking
Global Company Ranking for NGS Instruments in Drug Development
Global Company Ranking for NGS Consumables in Drug Development
Global Company Ranking for NGS Services in Drug Development

Chapter 13 Company Profiles

10X GENOMICS
AGILENT TECHNOLOGIES INC.
BGI (BEIJING GENOMICS INSTITUTE)
BIO-RAD LABORATORIES INC.
CD GENOMICS
ILLUMINA INC.
INTEGRATED DNA TECHNOLOGIES INC.
MICRONOMA
NEW ENGLAND BIOLABS
OXFORD NANOPORE TECHNOLOGIES
PACIFIC BIOSCIENCES OF CALIFORNIA INC.
PERKINELMER INC.
PROMEGA CORP.
PSOMAGEN INC.
PRECISION FOR MEDICINE, FORMERLY APOCELL
QIAGEN
ROCHE HOLDING AG
THERMO FISHER SCIENTIFIC INC.
TAKARA BIO INC.
TECAN GROUP LTD.

Chapter 14 Appendix: Acronyms

簡介目錄圖表

List of Tables

Summary Table : Global Market for NGS in Drug Development, by Region, Through 2028
Table 1 : DNA Translation and Transcription
Table 2 : Long-range DNA Structure
Table 3 : DNA Sequencing Workflow
Table 4 : DNA Sequencing Historical Timeline, 1955-2017
Table 5 : Sequencing Technology Development, 1990-2020+
Table 6 : Cost to Sequence a Single Human Genome, 2001-2018
Table 7 : Sanger Sequencing Summary
Table 8 : Sanger Sequencing Improvements
Table 9 : NGS Technologies
Table 10 : Roche NGS Workflow
Table 11 : Illumina NGS Workflow
Table 12 : Thermo Fisher NGS Workflow
Table 13 : NGS Instruments
Table 14 : Benchtop and Handheld Sequencer Platforms
Table 15 : Characteristics of NGS Platforms
Table 16 : NGS Bioinformatics Workflow
Table 17 : Sequence Annotation Steps
Table 18 : NGS Service Providers
Table 19 : NGS Cost per Sample
Table 20 : Future Challenges for Implementing NGS
Table 21 : Global Market for NGS in Drug Development, by Product Type, Through 2028
Table 22 : Global Market for NGS Instruments in Drug Development, by Region, Through 2028
Table 23 : Global Market for NGS Consumables in Drug Development, by Region, Through 2028
Table 24 : Global Market for NGS Services in Drug Development, by Region, Through 2028
Table 25 : Global Market for NGS in Drug Development, by End User, Through 2028
Table 26 : Global Market for NGS in Drug Development, by Region, Through 2028
Table 27 : North American Market for NGS in Drug Development, by Country, Through 2028
Table 28 : Asia-Pacific Market for NGS in Drug Development, by Country, Through 2028
Table 29 : European Market for NGS in Drug Development, by Country, Through 2028
Table 30 : RoW Market for NGS in Drug Development, Through 2028
Table 31 : Key Focus Areas in ESG Metrics
Table 32 : Net-Zero GHG Commitments, Major NGS Companies
Table 33 : ESG Rankings for Major NGS Companies, 2023*
Table 34 : CDP Scope Card for Major NGS Companies, 2022
Table 35 : U.S. Patent Related to NGS
Table 36 : Worldwide Patent Related to NGS
Table 37 : European Patents Related to NGS
Table 38 : Chinese Patents Related to NGS
Table 39 : Japanese Patents Related to NGS
Table 40 : Global Market Rankings, NGS in Drug Development, by Manufacturer, 2022
Table 41 : Global Market Rankings for NGS Instruments in Drug Development, by Manufacturer, 2022
Table 42 : Global Market Rankings for NGS Instruments in Drug Development, by Manufacturer, 2022
Table 43 : Global Market Rankings for NGS Services in Drug Development, by Manufacturer, 2022
Table 44 : 10x Genomics: Net Annual Revenue, by Segment, 2020-2022
Table 45 : 10x Genomics: Net Annual Revenue, by Region/Country, 2020-2022
Table 46 : 10x Genomics: Products and Services
Table 47 : Agilent Technologies Inc.: Net Revenue, by Segment, 2020-2022
Table 48 : Agilent Technologies Inc.: Net Revenue, by Business Segment, 2020-2022
Table 49 : Agilent Technologies Inc.: Net Revenue, by End Market, 2020-2022
Table 50 : Agilent Technologies Inc.: Revenue, by Type, 2020-2022
Table 51 : Agilent Technologies Inc.: Net Revenue, by Region, 2020-2022
Table 52 : Agilent Technologies Inc.: NGS Products
Table 53 : BGI: Products and Services
Table 54 : Bio-Rad Laboratories Inc.: Product Portfolio
Table 55 : Bio-Rad Laboratories Inc.: Company Financials, 2020-2022
Table 56 : Bio-Rad Laboratories Inc.: Net Revenue, by Business Segment, 2020-2022
Table 57 : Bio-Rad Laboratories Inc.: Net Revenue, by Region/Country, 2020-2022
Table 58 : Illumina Inc.: Net Revenue, 2020-2022
Table 59 : Illumina Inc.: Revenue, by Source, 2021 and 2022
Table 60 : Illumina Inc.: Net Revenue, by Region, 2020-2022
Table 61 : Illumina Inc.: Drug Discovery and Development Products
Table 62 : Oxford Nanopore Technologies: Products and Services
Table 63 : Oxford Nanopore Technologies: Net Revenue, by Segment, 2020-2022
Table 64 : Oxford Nanopore Technologies: LSRT Revenue, by Region/Country, 2020-2022
Table 65 : Pacific Biosciences of California Inc.: Net Revenue, by Segment, 2020-2022
Table 66 : Pacific Biosciences of California Inc.: Net Revenue, by Region, 2020-2022
Table 67 : PacBio: Products and Services
Table 68 : PerkinElmer Inc.: Net Revenue, by Operating Segment, 2020-2022
Table 69 : PerkinElmer Inc.: Net Revenue, by Business Segment, 2020-2022
Table 70 : PerkinElmer Inc.: Net Revenue, by Region/Country, 2020-2022
Table 71 : Qiagen: Financial Revenue, 2020-2022
Table 72 : Qiagen: Net Revenue, by Customer Class, 2020-2022
Table 73 : Qiagen: Net Revenue, by Product Group, 2020-2022
Table 74 : Qiagen: Net Revenue, by Region/Country, 2020-2022
Table 75 : Qiagen: NGS Products and Services
Table 76 : Roche Holding AG: Net Revenue, by Business Segment, 2020-2022
Table 77 : Roche Holding AG: Diagnostics Revenue, by Segment, 2020-2022
Table 78 : Roche Holding AG: Pharmaceuticals Revenue, by Segment, 2021 and 2022
Table 79 : Roche Holding AG: Net Revenue, by Region/Country, 2021 and 2022
Table 80 : Roche Holding AG: NGS Products and Services
Table 81 : Thermo Fisher Scientific Inc.: Net Revenue, by Segment, 2020-2022
Table 82 : Thermo Fisher Scientific Inc.: Net Revenue, by Segment, 2020-2022
Table 83 : Thermo Fisher Scientific Inc.: Net Revenue, by Region, 2020-2022
Table 84 : Thermo Fisher Scientific Inc.: Products and Services
Table 85 : Takara Bio Inc.: Net Revenue, by Segment, 2021 and 2022
Table 86 : Takara Bio Inc.: Net Revenue, by Region/Country, 2020-2022
Table 87 : Tecan Group Ltd.: Company Financials, 2020 and 2022
Table 88 : Tecan Group Ltd.: Net Revenue, by Business Segment, 2020-2022
Table 89 : Tecan Group Ltd.: Net Revenue, by Region, 2022
Table 90 : Acronyms Used in This Report

List of Figures

Summary Figure A : Global Market for NGS in Drug Development, by Region, 2020-2028
Summary Figure B : Global Market Shares of NGS in Drug Development, by Region, 2022
Figure 1 : Whole Genome Sequencing
Figure 2 : Number of NGS Tests, Research Activities, Different Global Centers, 2023
Figure 3 : The Road from NGS to Personalized Medicine
Figure 4 : Global Market for NGS in Drug Development, by Product Type, 2020-2028
Figure 5 : Global Market Shares of NGS in Drug Development, by Product Type, 2022
Figure 6 : Global Market for NGS Instruments in Drug Development, by Region, 2020-2028
Figure 7 : Global Market Shares of NGS Instruments in Drug Development, by Region, 2022
Figure 8 : Global Market for NGS Consumables in Drug Development, by Region, 2020-2028
Figure 9 : Global Market Shares of NGS Consumables in Drug Development, by Region, 2022
Figure 10 : Global Market for NGS Services in Drug Development, by Region, 2020-2028
Figure 11 : Global Market Shares of NGS Services in Drug Development, by Region, 2022
Figure 12 : Global Market for NGS in Drug Development, by End User, 2020-2028
Figure 13 : Global Market Shares of NGS in Drug Development, by End User, 2022
Figure 14 : Global Market for NGS in Drug Development, by Region, 2020-2028
Figure 15 : Global Market Shares of NGS in Drug Development, by Region, 2022
Figure 16 : North American Market for NGS in Drug Development, by Country, 2020-2028
Figure 17 : North American Market Shares of NGS in Drug Development, by Country, 2022
Figure 18 : Asia-Pacific Market for NGS in Drug Development, by Country, 2020-2028
Figure 19 : Asia-Pacific Market Shares of NGS in Drug Development, by Country, 2022
Figure 20 : European Market for NGS in Drug Development, by Country, 2020-2028
Figure 21 : European Market Shares of NGS in Drug Development, by Country, 2022
Figure 22 : How a Strong ESG Proposition Benefits Businesses
Figure 23 : Research Communities, Key Sustainable Practices, Research Laboratories
Figure 24 : Illumina Inc.'s Most Material ESG Issues
Figure 25 : Emerging Technologies in the NGS Market in Drug Development
Figure 26 : 10x Genomics: Net Revenue, 2020-2022
Figure 27 : 10x Genomics: Revenue Share, by Segment, 2022
Figure 28 : 10x Genomics: Revenue Share, by Region/Country, 2022
Figure 29 : Agilent Technologies Inc.: Revenue Share, by Segment, 2022
Figure 30 : Agilent Technologies Inc.: Revenue Share, by Business Segment, 2022
Figure 31 : Agilent Technologies Inc.: Revenue Share, by End Market, 2022
Figure 32 : Agilent Technologies Inc.: Revenue Share, by Type, 2022
Figure 33 : Agilent Technologies Inc.: Revenue Share, by Region, 2022
Figure 34 : Bio-Rad Laboratories Inc.: Revenue Share, by Business Segment, 2022
Figure 35 : Bio-Rad Laboratories Inc.: Revenue Share, by Region/Country, 2022
Figure 36 : Illumina Inc.: Revenue Share, by Segment, 2022
Figure 37 : Illumina Inc.: Revenue Share, by Segment, 2022
Figure 38 : Oxford Nanopore Technologies: Net Revenue, 2020-2022
Figure 39 : Oxford Nanopore Technologies: Revenue Share, by Region/Country, 2022
Figure 40 : Pacific Biosciences of California Inc.: Revenue Share, by Segment, 2022
Figure 41 : Pacific Biosciences of California Inc.: Revenue Share, by Region, 2022
Figure 42 : PerkinElmer Inc.: Revenue Share, by Operating Segment, 2022
Figure 43 : PerkinElmer Inc.: Revenue Share, by Business Segment, 2022
Figure 44 : PerkinElmer Inc.: Revenue Share, by Region/Country, 2022
Figure 45 : Qiagen: Revenue Share, by Segment, 2022
Figure 46 : Qiagen: Revenue Share, by Customer Class, 2022
Figure 47 : Qiagen: Revenue Share, by Product Group, 2022
Figure 48 : Qiagen: Revenue Share, by Region/Country, 2022
Figure 49 : Roche Holding AG: Revenue Share, by Business Segment, 2022
Figure 50 : Roche Holding AG: Diagnostics Revenue Share, by Segment, 2022
Figure 51 : Roche Holding AG: Pharmaceuticals Revenue Share, by Segment, 2022
Figure 52 : Roche Holding AG: Revenue Share, by Region/Country, 2022
Figure 53 : Thermo Fisher Scientific Inc.: Net Revenue, 2020-2022
Figure 54 : Thermo Fisher Scientific Inc.: Revenue Share, by Segment, 2022
Figure 55 : Thermo Fisher Scientific Inc.: Revenue Share, by Segment, 2022
Figure 56 : Thermo Fisher Scientific Inc.: Revenue Share, by Region, 2022
Figure 57 : Takara Bio Inc.: Net Revenue, 2020-2022
Figure 58 : Takara Bio Inc.: Revenue Share, by Segment, 2022
Figure 59 : Takara Bio Inc.: Revenue Share, by Region/Country, 2022
Figure 60 : Tecan Group Ltd.: Revenue Share, by Business Segment, 2022
Figure 61 : Tecan Group Ltd.: Revenue Share, by Region, 2022